{
    "nct_id": "NCT05062317",
    "official_title": "Risk-Stratified Adjuvant Therapy: CtDNA-Directed Post-Hepatectomy Chemotherapy for Patients with Resectable Colorectal Liver Metastases",
    "inclusion_criteria": "* Patients ≥18 years of age with CLM undergoing elective hepatectomy with curative intent (primary colorectal primary cancer previously removed OR being removed at time of hepatectomy) after preoperative chemotherapy (i.e., FOLFOX/FOLFIRI +/- bevacizumab or panitumumab/cetuximab) from 07/01/2021 - 12/31/2023\n* Must receive ≥ 4 cycles of preoperative chemotherapy\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients with primary colorectal tumor that will remain in situ\n* Inability to undergo postoperative chemotherapy, or postoperative chemotherapy not planned a priori\n* Unwilling/unable to undergo blood draws for ctDNA, patient or provider-determined\n* Other active malignancies requiring treatment\n* Women who are pregnant",
    "miscellaneous_criteria": ""
}